Corcept Therapeutics (CORT) Change in Accured Expenses (2010 - 2026)

Corcept Therapeutics (CORT) has 17 years of Change in Accured Expenses data on file, last reported at -$9.4 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses fell 59.72% year-over-year to -$9.4 million; the trailing twelve-month figure through Mar 2026 stood at $422000.0 (down 98.19% YoY), and the FY2025 full-year result was $3.9 million, down 89.73% from the prior year.
• Change in Accured Expenses climbed to -$9.4 million in Q1 2026, from -$13.2 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $19.6 million in Q3 2024 to a low of -$19.0 million in Q4 2023.
• A 5-year average of $3.1 million and a median of $5.0 million in 2022 frame the typical range for Change in Accured Expenses.
• Across the five-year window, Change in Accured Expenses tumbled 1714.07% in 2023 and jumped 586.91% in 2025, its largest moves.
• Tracing CORT's Change in Accured Expenses over 5 years: stood at $1.2 million in 2022, then plunged by 1714.07% to -$19.0 million in 2023, then jumped by 156.24% to $10.7 million in 2024, then slumped by 223.57% to -$13.2 million in 2025, then grew by 29.16% to -$9.4 million in 2026.
• Business Quant data shows CORT's Change in Accured Expenses at -$9.4 million in Q1 2026, -$13.2 million in Q4 2025, and $17.2 million in Q3 2025.